ES2152953T3 - Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. - Google Patents
Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.Info
- Publication number
- ES2152953T3 ES2152953T3 ES93921129T ES93921129T ES2152953T3 ES 2152953 T3 ES2152953 T3 ES 2152953T3 ES 93921129 T ES93921129 T ES 93921129T ES 93921129 T ES93921129 T ES 93921129T ES 2152953 T3 ES2152953 T3 ES 2152953T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- hemostatic
- specific antibodies
- intact proteins
- compounds lack
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
METODOS PARA LA GENERACION DE ANTICUERPOS CA2+ INDEPENDIENTES, CONTRA FACTORES DE COAGULACION SANGUINEA, EMPLEANDO ESTRATEGIA DE SELECCION DE ANTICUERPOS, BASADA EN PEQUEÑOS PEPTIDOS QUE ESTAN COMPRENDIENDO SECUENCIAS OBJETIVO PARA PROTEOLISIS LIMITADA. ESTOS ANTICUERPOS, QUE SUSTANCIALMENTE SE DISTINGUEN ENTRE ESPECIES INTACTAS Y SEGMENTADAS DE LA CITADA PROTEINA HEMOSTATICA, PROPORCIONAN MEDIOS NUEVOS PARA EL AISLAMIENTO DE PROTEINAS HEMOSTATICAS INTACTAS. DEBIDO A LA AUSENCIA DE PRODUCTOS DE SEGMENTACION, QUE USUALMENTE SE ASOCIAN CON EFECTOS SECUNDARIOS O EFICACIA REDUCIDA, ESTAS PROTEINAS INTACTAS PUEDEN SERVIR COMO AGENTES DE PERFECCIONAMIENTO EN COMPOSICIONES TERAPEUTICAS PARA EL TRATAMIENTO DE TRASTORNOS HEMOSTATICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92202615 | 1992-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2152953T3 true ES2152953T3 (es) | 2001-02-16 |
Family
ID=8210886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93921129T Expired - Lifetime ES2152953T3 (es) | 1992-08-27 | 1993-08-26 | Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. |
Country Status (12)
Country | Link |
---|---|
US (2) | US5932706A (es) |
EP (1) | EP0658168B1 (es) |
JP (1) | JP3735112B2 (es) |
AT (1) | ATE197590T1 (es) |
AU (1) | AU678987B2 (es) |
CA (1) | CA2143125C (es) |
DE (1) | DE69329682T2 (es) |
DK (1) | DK0658168T3 (es) |
ES (1) | ES2152953T3 (es) |
GR (1) | GR3035391T3 (es) |
PT (1) | PT658168E (es) |
WO (1) | WO1994005692A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
US7109170B2 (en) * | 1999-06-16 | 2006-09-19 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
US6624289B1 (en) * | 1999-06-16 | 2003-09-23 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
US20040102388A1 (en) * | 2000-03-22 | 2004-05-27 | High Katherine A. | Modified blood clotting factors and methods of use |
HUP0402315A3 (en) | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
CN1671410B (zh) | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的稳定化固体组合物 |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
AU2004241698A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
CA2534028A1 (en) | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
FR2863616A1 (fr) * | 2003-12-12 | 2005-06-17 | Stago Diagnostica | Dosage de la proteine s libre non clivee par le facteur xa et utilisation de ce dosage pour l'evaluation du potentiel de coagulation |
PL1831242T3 (pl) * | 2004-12-23 | 2013-04-30 | Novo Nordisk Healthcare Ag | Zmniejszanie zawartości zanieczyszczeń białkowych w kompozycjach zawierających zależne od witaminy K białko będące przedmiotem zainteresowania |
WO2007006808A1 (en) * | 2005-07-13 | 2007-01-18 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
CN106967150B (zh) | 2010-04-29 | 2020-12-04 | 百深公司 | 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法 |
EP2748180B1 (en) | 2011-10-14 | 2018-08-15 | Baxalta GmbH | Protein purification by anion exchange chromatography |
US10378004B2 (en) * | 2011-10-14 | 2019-08-13 | Baxalta GmbH | Protein purification by anion exchange chromatography |
PL2970376T3 (pl) | 2013-03-15 | 2018-10-31 | Baxalta Incorporated | Sposób oczyszczania białek zależnych od witaminy k za pomocą chromatografii anionowymiennej |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252712A (en) * | 1980-10-20 | 1993-10-12 | New England Medical Center Hospitals, Inc. | Purified antibodies which specifically bind human abnormal prothrombin |
US5055557A (en) * | 1983-03-04 | 1991-10-08 | Scripps Clinic & Research Foundation | Ultrapurification of factor IX and other vitamin K-dependent proteins |
US4637932A (en) * | 1984-10-15 | 1987-01-20 | Miles Laboratories, Inc. | Process for producing a concentrate enriched in coagulation factors VII and VIIa |
EP0229026B1 (en) * | 1986-01-06 | 1995-11-22 | Blood Systems Inc, an Arizona not-for-profit corporation | Therapeutic blood product, means and methods of preparing same |
DE3740520A1 (de) * | 1987-11-30 | 1989-06-08 | Hans Dr Rer Nat Scheefers | Schnelles verfahren zur gewinnung einer faktor vii - praeparation sowie ihre verwendung |
FI86339C (fi) * | 1988-12-09 | 1992-08-10 | Ari Tuomi | Diffusionscell foer undersoekning av salvor och liknande. |
US5202253A (en) * | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
CA2006684C (en) * | 1988-12-30 | 1996-12-17 | Charles T. Esmon | Monoclonal antibody against protein c |
AT402153B (de) * | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
DK0573605T3 (da) * | 1991-03-01 | 2001-01-02 | Rhone Poulenc Rorer Int | Fremstilling af faktor IX |
DE4329517C2 (de) * | 1993-08-30 | 1996-04-04 | Schuelke & Mayr Gmbh | Waschende Händedesinfektions- und Händedekontaminationsmittel auf Basis naturidentischer, aromatischer Alkohole |
AU674586B2 (en) * | 1994-07-27 | 1997-01-02 | Rain Bird Sprinkler Manufacturing Corporation | Speed controlled rotating sprinkler |
-
1993
- 1993-08-26 ES ES93921129T patent/ES2152953T3/es not_active Expired - Lifetime
- 1993-08-26 DK DK93921129T patent/DK0658168T3/da active
- 1993-08-26 AT AT93921129T patent/ATE197590T1/de active
- 1993-08-26 CA CA002143125A patent/CA2143125C/en not_active Expired - Lifetime
- 1993-08-26 AU AU48359/93A patent/AU678987B2/en not_active Ceased
- 1993-08-26 JP JP50706994A patent/JP3735112B2/ja not_active Expired - Fee Related
- 1993-08-26 DE DE69329682T patent/DE69329682T2/de not_active Expired - Lifetime
- 1993-08-26 EP EP93921129A patent/EP0658168B1/en not_active Expired - Lifetime
- 1993-08-26 PT PT93921129T patent/PT658168E/pt unknown
- 1993-08-26 WO PCT/NL1993/000174 patent/WO1994005692A1/en active IP Right Grant
-
1997
- 1997-02-10 US US08/797,842 patent/US5932706A/en not_active Ceased
-
2000
- 2000-07-17 US US09/618,592 patent/USRE38202E1/en not_active Expired - Lifetime
-
2001
- 2001-02-07 GR GR20010400218T patent/GR3035391T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE197590T1 (de) | 2000-12-15 |
DK0658168T3 (da) | 2001-01-22 |
US5932706A (en) | 1999-08-03 |
WO1994005692A1 (en) | 1994-03-17 |
DE69329682T2 (de) | 2001-05-17 |
JPH08500833A (ja) | 1996-01-30 |
PT658168E (pt) | 2001-04-30 |
AU4835993A (en) | 1994-03-29 |
CA2143125A1 (en) | 1994-03-17 |
EP0658168A1 (en) | 1995-06-21 |
GR3035391T3 (en) | 2001-05-31 |
EP0658168B1 (en) | 2000-11-15 |
DE69329682D1 (de) | 2000-12-21 |
AU678987B2 (en) | 1997-06-19 |
CA2143125C (en) | 2008-09-23 |
USRE38202E1 (en) | 2003-07-22 |
JP3735112B2 (ja) | 2006-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2152953T3 (es) | Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. | |
DK532284A (da) | Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser | |
ES2129487T3 (es) | Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion. | |
ATE177754T1 (de) | Fragmente von prion proteinen. | |
WO1996040885A3 (en) | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION | |
DE69813212D1 (de) | Verfahren zur erzeugung von proteinhydrolysaten | |
DE69703449T2 (de) | Neuroaktive peptide | |
AU640699B2 (en) | Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor | |
GR3018371T3 (en) | Method for identifying or determining proteins and applications therefor. | |
FR2816410B1 (fr) | Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire | |
DE69535060D1 (de) | Dimere des kleeblatt-proteins | |
AU612683B2 (en) | Synthetic peptides, antibodies directed against them, and the use thereof | |
DK0909388T3 (da) | Immunologisk assay til spongiforme encephalopatier | |
ID19063A (id) | Pereaksi peptida untuk deteksi cytomegalovirus (cmv) | |
DE69621837D1 (de) | Methoden zur feststellung von alzheimerscher krankheit | |
AU3563397A (en) | Methods for determining the presence of brain protein s-100 | |
DK0607425T3 (da) | Epstein-Barr-viruspeptider og antistoffer mod disse peptider | |
ES2113492T3 (es) | Metodo de valoracion de fibrinogeno, reactivo seco para dicha valoracion, y procedimiento para su preparacion. | |
AR002004A1 (es) | Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica. | |
ATE301674T1 (de) | Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie | |
Li et al. | Cross reactivities of monoclonal antibodies against hemorrhagic toxins of Prairie rattlesnake (Crotalus viridis viridis) venom | |
Srinivas et al. | Translocation of plasminogen activator inhibitor-1 during serum stimulated growth of mouse embryo fibroblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 658168 Country of ref document: ES |